AzTrials
AzTrials

Heart FailurePhase 3SELEQT-HFNCT07234422

The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.

A Phase 3 study testing Selenium/CoQ10 in people with Heart Failure, run by Netherlands Heart Institute at 7 sites in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
Selenium/CoQ10
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,100 participants
Where
7 sitesNetherlands
Study dates
4 May 2026to Dec 2030
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age >18 years
  • Outpatients with chronic HF, NYHA II - ambulatory IV
  • Serum NT-proBNP concentrations >600 pg/mL (71 pmol/L) if in sinus rhythm; >1000pg/mL (118 pmol/L) if in Atrial fibrillation*

Who cannot join

  • History of myocardial infarction, myocarditis, percutaneous intervention, cardiac surgery or stroke <30 days
  • The presence of a mechanical assist device
  • Scheduled for mechanical assist device or heart transplant
  • Other non-cardiac conditions with limited life expectancy (<1 year)
  • Amyloid, hypertrophic obstructive or constrictive cardiomyopathy
  • End stage kidney disease for which chronic intermittent peritoneal or haemodialysis
Show all 9Show fewer
  • Unable to sign informed consent
  • (Unwilling to stop) use of over the counter supplements coQ10/selenium
  • Peanut and/or soy allergy

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

SELEQT-HF Study Team contact

+31 (0)503616161

seleqt-hf@umcg.nl

7 sites in 1 country

Netherlands7 sites, 7 recruiting

  • Noordwest Ziekenhuisgroep

    Alkmaar

    Jan van Ramshorst, MD, PhD, 0031725484444, seleqt-hf@umcg.nl

    Not yet recruiting

  • AUMC

    Amsterdam

    Marielle C van de Veerdonk, MD, PhD, 0031205669111, seleqt-hf@umcg.nl

    Not yet recruiting

  • Amphia Ziekenhuis

    Breda

    Jeroen Schaap, MD, PhD, 0031765955000, seleqt-hf@umcg.nl

    Recruiting

  • Catharina ziekenhuis Eindhoven

    Eindhoven

    René Tio, MD, PhD, 0031402399111, seleqt-hf@umcg.nl

    Not yet recruiting

  • TREANT

    Emmen

    Solmaz Assa, MD, PhD, 0031881292929, seleqt-hf@umcg.nl

    Not yet recruiting

  • University Medical Center Groningen

    Groningen, 9713GZ

    Kevin Damman, MD, PhD, 0031503616161, seleqt-hf@umcg.nl

    Peter van der Meer, Prof Dr, 0031503616161, seleqt-hf@umcg.nl

    Recruiting

  • St Antonius ziekenhuis

    Nieuwegein

    Geert PJ van Hout, MD, PhD, 0031883203000, seleqt-hf@umcg.nl

    Not yet recruiting

Other trials in Netherlands

About this study

Official title: A Registry-Based Randomised Controlled Trial With Heart 4 Data - SELEnium and CoQ10 NuTrition for Heart Failure: H4D-SELEQT-HF

The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease.

Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes.

Read more

Participants will:

Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment

Attend standard clinical visits according to routine clinical care.

The study will include 1,100 adults with chronic heart failure. Selenium and CoQ10 are natural nutrients with no known health risks. If effective, this supplement could provide a safe new way to improve outcomes for people with heart failure.

Read the detailed description

This randomized controlled trial will be a pragmatic registry based clinical trial (RBRCT), using existing infrastructure on quality reporting of cardiovascular disease management in the Netherlands. This registration platform (Netherlands Heart Registration (NHR) forms the basis of incorporating information of patients with HF in hospitals in the Netherlands. Using the data gathered through this registry, these data will serve as source documentation for the electronic case report form of the current RBRCT and requires only limited additional information. Through the same system, randomization, (Serious) adverse event reporting, endpoint reporting and investigational product allocation will be conducted. Investigational product (selenium/CoQ10 supplementation or placebo) will be distributed from central pharmacy to the home of the patient. Apart from telephone calls at 6 months after randomization and every 12 months thereafter, there will be no study visits and the data gathering will be conducted through routine clinical care and registrations that are already in place. SELEQT-HF is an event driven RBRCT, with an expected median follow up of 2 years.

Conditions
Heart Failure
Being tested
Selenium/CoQ10, Matching Placebo (B)
Keywords
heart failure, selenium, coQ10, registry based randomized clinical trial
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Selenium/CoQ10Dietary supplement

    Oral dosage of twice daily Selenium/CoQ10 (2 x 100 μg selenium tablets (SelenoPrecise 100 μg, Pharma Nord, Denmark) and 2 x 100 mg Q10 capsules (Bio-Quinon 100 mg B.I.D, Pharma Nord, Denmark)

  • Matching Placebo (B)Drug

    Matching Placebo

Study groups in NCT07234422
Study groupRoleWhat they receive
Selenium/CoQ10ExperimentalOral dosage of twice daily Selenium/CoQ10 (2 x 100 μg selenium tablets (SelenoPrecise 100 μg, Pharma Nord, Denmark) and 2 x 100 mg Q10 capsules (Bio-Quinon 100 mg B.I.D, Pharma Nord, Denmark)
Receives: Dietary Supplement: Selenium/CoQ10
PlaceboPlacebo comparatorNot described
Receives: Drug: Matching Placebo (B)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite of repeated HF hospitalization, repeated urgent HF visits and cardiovascular death

    Total (first and subsequent) HF hospitalizations, urgent visits for HF visits and cardiovascular deaths with selenium/coQ10 compared to placebo.

    Measured: ongoing, up to ~30 months

Secondary outcomes (3)

  1. Total number of events of (repeated) HF hospitalization and (repeated) urgent HF visits

    Total number of (repeated) HF hospitalization and (repeated) urgent HF visits

    Measured: ongoing, up to ~30 months

  2. Time to death from any cause

    time to death from any cause with selenium/coQ10 compared to placebo

    Measured: ongoing, up to ~30 months

  3. Time to cardiovascular death

    Time to cardiovascular death with selenium/coQ10 compared to placebo

    Measured: ongoing, up to ~30 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2025
  2. Study start4 May 2026
  3. Primary completionDec 2030 (estimated)
  4. Study completionDec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
1,100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07234422
Sponsor's protocol ID
NL87982.042.24
Other IDs
METc 2025/02
Acronym
SELEQT-HF
Status last verified
May 2026
First submitted
14 Nov 2025
Last updated
19 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013 Sep 1;167(5):1860-6. doi: 10.1016/j.ijcard.2012.04.156. Epub 2012 May 23.

    PubMed 22626835

  • Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP; Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014 Dec;2(6):641-9. doi: 10.1016/j.jchf.2014.06.008. Epub 2014 Oct 1.

    PubMed 25282031

  • Bomer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, IJmker J, Anker SD, Cleland JGF, Hillege HL, Lang CC, Ng LL, Samani NJ, Tromp J, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P. Selenium and outcome in heart failure. Eur J Heart Fail. 2020 Aug;22(8):1415-1423. doi: 10.1002/ejhf.1644. Epub 2019 Dec 6.

    PubMed 31808274

  • Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Feb;82(3):901-4. doi: 10.1073/pnas.82.3.901.

    PubMed 3856239

  • McKeag NA, McKinley MC, Harbinson MT, McGinty A, Neville CE, Woodside JV, McKeown PP. Dietary Micronutrient Intake and Micronutrient Status in Patients With Chronic Stable Heart Failure: An Observational Study. J Cardiovasc Nurs. 2017 Mar/Apr;32(2):148-155. doi: 10.1097/JCN.0000000000000322.

    PubMed 26829748

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Selenium/CoQ10 in people with Heart Failure, run by Netherlands Heart Institute at 7 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact SELEQT-HF Study Team (+31 (0)503616161, seleqt-hf@umcg.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite of repeated HF hospitalization, repeated urgent HF visits and cardiovascular death (time frame: ongoing, up to ~30 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07234422, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in